Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
BUSINESS
Sosei, Pfizer Nominate 3rd Development Candidate Compound
Sosei Group said on December 24 that its partner Pfizer has nominated an oral small molecule targeting a G protein-coupled receptor (GPCR) associated with metabolic and other diseases as a clinical development candidate under their drug discovery collaboration deal. Sosei…
To read the full story
Related Article
- Third GPCR-Targeted Drug Enters Clinic under Sosei/Pfizer Collaboration
May 20, 2021
- 2nd GPCR-Targeted Candidate Enters Clinic under Sosei/Pfizer’s Drug Discovery Alliance
September 29, 2020
- Sosei Bags US$3 Million from Genentech on Nomination of New GPCR Disease Target
October 10, 2019
- Luring Big Pharma with GPCR Work, Sosei Heptares Treads Its Own Path to Pursue Small Molecule Targets
September 18, 2019
- Sosei, Takeda Seal Multi-Target Collaboration Deal
August 6, 2019
- Heptares Inks R&D Deal with Pfizer; Pfizer to Buy 3% Stake in Sosei for US$33 Million
December 2, 2015
BUSINESS
- Astellas on Track to Hit 30% Margin Goal Early after Strong H1 Scorecards
November 5, 2026
- Nxera Inks US$1.47 Billion Deal with AbbVie for IBD Drug
November 5, 2026
- Kissei Might Revise Midterm Targets as Tavneos Faces Approval Revocation
November 5, 2026
- Boehringer, Lung Cancer Society Launch 5-Year Hernexeos Real-World Study
November 5, 2026
- ASKA Snags Japan Rights to Minghui’s TED Therapy
November 5, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…